Skin & aging Signal peptide
Acetyl tetrapeptide-5
Regulatory status
Status at a glance
503A compounding status
Not nominated
We found no pending nomination for the 503A bulks list. Unless the substance has another legal pathway (for example, a USP monograph or use in an FDA-approved drug), 503A pharmacies generally may not compound with it.
- Also known as
- Eyeseryl
- FDA approval
- Not FDA-approved for any use
- 503B outsourcing
- Not determined
- Anti-doping (WADA)
- Not on the WADA Prohibited List
- DEA schedule
- Not a controlled substance
About peptide status
Most peptides discussed here are not FDA-approved for any use, and products labeled “research use only” are not for human use. Removal from Category 2 does not authorize compounding. PCAC votes are non-binding recommendations; FDA and HHS make the final decisions.
This is not medical or legal advice, and we do not publish dosing, sourcing or reconstitution information. Talk with a licensed clinician before using any peptide.
If you think you are having a medical emergency, call 911.
Key takeaway
Acetyl tetrapeptide-5, sold in skincare as Eyeseryl, is a synthetic four-amino acid peptide used in eye creams to soften the look of under-eye bags and puffiness. It is thought to work in two ways, by easing the fluid buildup that makes the under-eye area look swollen and by limiting the glycation that stiffens collagen, though its published evidence comes almost entirely from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
At a glance
- What it is
- Synthetic peptide used in anti-aging and eye-care skincare, best known by the trade name Eyeseryl
- Main uses
- Marketed mainly to reduce the appearance of under-eye puffiness and bags, through a proposed anti-edema and anti-glycation action
- FDA status
- Cosmetic ingredient rather than a drug, so does not require FDA approval
- Evidence strength
- Low research
Summary
Acetyl tetrapeptide-5, sold as Eyeseryl, is a cosmetic peptide used in eye creams for puffiness. See how it is thought to work and how limited the evidence is.
What is acetyl tetrapeptide-5?
Acetyl tetrapeptide-5 is a synthetic peptide of four amino acids used as a cosmetic ingredient, best known by the trade name Eyeseryl, developed by the ingredient maker Lipotec, now part of Lubrizol. It is a small "signal" peptide, meaning it is designed to interact with skin biology rather than simply sit on the surface, and it is sold almost exclusively in products aimed at the under-eye area.
It is applied topically, usually in eye creams, serums, and gels marketed to reduce the look of puffiness and bags.
How does it work?
Acetyl tetrapeptide-5 is thought to reduce the appearance of under-eye bags through two proposed actions:
- An anti-edema effect. Puffiness under the eyes is partly caused by fluid pooling in the tissue, and in the manufacturer's testing the peptide reduced that fluid buildup, in part by lowering the leakiness of small blood vessels, their vascular permeability, so that less fluid escapes into the surrounding skin.
- An effect on glycation, the process in which sugars bind to and stiffen collagen. By limiting glycation, the peptide is proposed to help the thin skin under the eyes stay more elastic and less prone to the slackening that deepens the look of bags.
Both of these are findings from laboratory and manufacturer studies rather than independent clinical research. As with any topical peptide, how much of it actually crosses the skin barrier to reach the tissue underneath is uncertain, and that places a ceiling on how strong the effect can be.
Is it FDA-approved?
Safety note
Status: Cosmetic ingredient rather than a drug, so does not require FDA approval
Category: Cosmetic and topical · Primary body area: Skin & aging
No, and it does not need to be. The FDA does not approve cosmetics or most cosmetic ingredients before they go on the market. Cosmetics must be safe when used as directed and properly labeled, but there is no pre-market approval step the way there is for drugs, so no de-puffing or anti-aging peptide in a serum is "FDA-approved."
The distinction that matters for an ingredient like this is the line between a cosmetic and a drug. A product is a cosmetic when it is intended to improve appearance, but if it claims to change the structure or function of the body, the FDA can regulate it as an unapproved drug. This is why de-puffing claims are written around the appearance of the under-eye area rather than a promised physiological change.
What is it used for?
Acetyl tetrapeptide-5 is used almost entirely in topical eye-care products, where it is included to reduce the appearance of under-eye puffiness, bags, and swelling. It often appears alongside ingredients such as caffeine or hyaluronic acid in eye creams, serums, and gels, and some formulas also position it as helping the under-eye skin look firmer and smoother.
What does the research show?
Editor’s note
Evidence strength: Low research
Its human evidence is limited mainly to manufacturer panel studies, with no independent, peer-reviewed clinical trial, so the cosmetic benefit is largely unverified despite a plausible anti-edema mechanism.
The published evidence for acetyl tetrapeptide-5 is thin and comes mostly from its manufacturer. Lipotec's own panel studies report a visible reduction in the appearance of under-eye bags and puffiness in volunteers who used a formulation containing the peptide, but those results have not been reproduced in independent, peer-reviewed clinical trials. So while the proposed mechanism is reasonable and the manufacturer data is encouraging, the cosmetic benefit rests largely on the company's own testing rather than on strong outside evidence.
What are the side effects?
Topical acetyl tetrapeptide-5 is generally considered well tolerated, with the low potential for irritation typical of cosmetic peptides, and it is used on the especially delicate skin around the eyes. As with any skincare ingredient, some people can still experience mild redness, stinging, or an allergic reaction, so patch testing before regular use and keeping the product out of the eyes themselves is sensible.
Sources: mechanism and efficacy claims are drawn from the ingredient manufacturer (Lipotec/Lubrizol, Eyeseryl) and ingredient references such as INCIDecoder; regulatory framing from FDA guidance on how cosmetics are regulated. This document is educational and does not constitute medical advice or a treatment claim.
Registered human trials
0 registered human trials on ClinicalTrials.gov that we reviewed
Sources
- [1]
- [2]
- [3]
- [4]
Compare every peptide’s status in the peptide regulatory status database
More for Skin & aging
View all skin & aging peptides →- Cosmetic & topical Skin & aging
Acetyl-Hexapeptide-8
Argireline
Acetyl hexapeptide-8, sold in skincare as Argireline, is a synthetic peptide modeled on the nerve protein SNAP-25 and marketed as a topical, "Botox-like" way to soften the appearance of expression lines. In lab and small clinical studies it interferes with the SNARE complex that nerves use to trigger muscle contraction, and a 2013 randomized study found it reduced the appearance of peri-orbital wrinkles over four weeks. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Moderate.
- Cosmetic & topical Skin & aging
Acetyl-Octapeptide-3
SNAP-8
Acetyl octapeptide-3, sold in skincare as SNAP-8, is a synthetic eight-amino acid peptide modeled on the nerve protein SNAP-25 and marketed as a stronger successor to Argireline for softening the appearance of expression lines. Like Argireline, it is designed to interfere with the SNARE complex that nerves use to trigger muscle contraction, but its own published human evidence is thin and comes mostly from the manufacturer. It is a cosmetic ingredient rather than a drug, so it does not require FDA approval, and its evidence is rated Low.
- FDA-approved Skin & aging
Afamelanotide
Afamelanotide is a synthetic, longer-lasting analog of alpha-melanocyte-stimulating hormone (α-MSH) that activates the MC1R receptor on pigment cells to boost the skin's own protective eumelanin. The FDA approved it in 2019 as Scenesse, a subcutaneous implant for adults with erythropoietic protoporphyria (EPP), a rare light-sensitivity disorder. In the pivotal 2015 placebo-controlled trials, U.S. patients (94) logged a median 69.4 pain-free hours in direct sunlight versus 40.8 on placebo (P = 0.04). EU patients (74) logged 6.0 versus 0.8 hours (P = 0.005).
- FDA-approved Skin & aging
Bacitracin
Bacitracin is a cyclic polypeptide antibiotic produced by Bacillus bacteria that kills gram-positive bacteria by blocking the construction of their cell wall. It is best known as an over-the-counter topical ointment for preventing infection in minor cuts, scrapes, and burns, often combined with neomycin and polymyxin B in "triple antibiotic" products. It is widely available over the counter, but it is also a common cause of allergic skin reactions, and its injectable form was withdrawn over kidney-toxicity concerns.
- Cosmetic & topical Skin & aging
Carnosine
Carnosine is a naturally occurring dipeptide, made of the amino acids beta-alanine and histidine, used in skincare as an antioxidant ingredient. Laboratory and ex-vivo skin studies suggest it can neutralize reactive oxygen species and limit glycation, a process in which sugars stiffen skin proteins, which is the rationale for using it in products aimed at the appearance of aging skin. As of 2026, the evidence for topical carnosine is largely from lab and ex-vivo studies rather than large human appearance trials.
- Cosmetic & topical Skin & aging
Copper-Tripeptide-1
GHK-Cu
Copper tripeptide-1, often called GHK-Cu, is a three-amino acid peptide (glycine-histidine-lysine) bound to a copper ion and used in skincare for its proposed role in skin renewal. Laboratory and animal studies show it can signal cells to make collagen and other matrix components. Independent human evidence is thin. In a randomized trial of 13 patients after CO2 laser resurfacing, GHK-Cu skincare showed no significant difference in redness or skin quality in blinded evaluations, though patients rated their overall skin quality higher (p = 0.04). As of 2026 it is a cosmetic ingredient, not an FDA-approved drug.